Analysis of field of temperature of power electronic systems in COMSOL MULTIPHYSICS environment

The paper deals with analysis of temperature field in power electronic devices using COMSOL MULTIPHYSICS software. It includes relevant problem of designing, specifically a power semiconductor converter. Till now, there has been one-dimensional interpretation of analysis considering heat transfer by conduction. Presented method results directly from differential equations of system heat balance, whereby heat transfer by conduction, flow and radiation is considered. The results can be animated in 3D view which enables analyzing the space-division switching network in power electronic device

Key competences formation and effective support of students mobility at technology faculties: modeling, design and assessment of flexible education concept

The paper brings the results of the current national educational agency project research of effectiveness of the modular didactic cycle with new technologies, methods and forms in student-focused concept through the processing of experimental data of the electronics study program from the period of 2016-2017. Data were collected from contributions kept by the students groups during the preparation phase and also from reflective final phase of the research period. Also, the presented solution and results of the project are directed at the main component of the educational process – the content of education and its compatibility with the technological trends in the actual working environment. The results show that digitization of the learning content and flexibility of design of educational modules with multimedia components are dominant and indicate compatibility with the trends of flexible educational environment. In addition, the results of project illustrates that even the change can be difficult, success can be attained in the most heterogeneous diversification of university education and mobility of graduates of technical universities that will contribute to increase of educational efficiency and will encourage arrival of investments to innovative entrepreneur projects and, mainly, will help national firms to succeed at EU and world market by strengthening of the dominant subject which produces values – the technical field graduate with the key competences for the 21st century needs

Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: A randomized clinical trial

IMPORTANCE Low-molecular-weight heparin is recommended over warfarin for the treatment of acute venous thromboembolism (VTE) in patients with active cancer largely based on results of a single, large trial. OBJECTIVE To study the efficacy and safety of tinzaparin vs warfarin for treatment of acute, symptomatic VTE in patients with active cancer. DESIGN, SETTINGS, AND PARTICIPANTS A randomized, open-label study with blinded central adjudication of study outcomes enrolled patients in 164 centers in Asia, Africa, Europe, and North, Central, and South America between August 2010 and November 2013. Adult patients with active cancer (defined as histologic diagnosis of cancer and receiving anticancer therapy or diagnosed with, or received such therapy, within the previous 6 months) and objectively documented proximal deep vein thrombosis (DVT) or pulmonary embolism, with a life expectancy greater than 6 months and without contraindications for anticoagulation, were followed up for 180 days and for 30 days after the last study medication dose for collection of safety data. INTERVENTIONS Tinzaparin (175 IU/kg) once daily for 6 months vs conventional therapy with tinzaparin (175 IU/kg) once daily for 5 to 10 days followed by warfarin at a dose adjusted to maintain the international normalized ratio within the therapeutic range (2.0-3.0) for 6 months. MAIN OUTCOMES AND MEASURES Primary efficacy outcome was a composite of centrally adjudicated recurrent DVT, fatal or nonfatal pulmonary embolism, and incidental VTE. Safety outcomes included major bleeding, clinically relevant nonmajor bleeding, and overall mortality. RESULTS Nine hundred patients were randomized and included in intention-to-treat efficacy and safety analyses. Recurrent VTE occurred in 31 of 449 patients treated with tinzaparin and 45 of 451 patients treated with warfarin (6-month cumulative incidence, 7.2% for tinzaparin vs 10.5% for warfarin; hazard ratio [HR], 0.65 [95% CI, 0.41-1.03]; P = .07). There were no differences in major bleeding (12 patients for tinzaparin vs 11 patients for warfarin; HR, 0.89 [95% CI, 0.40-1.99]; P = .77) or overall mortality (150 patients for tinzaparin vs 138 patients for warfarin; HR, 1.08 [95% CI, 0.85-1.36]; P = .54). A significant reduction in clinically relevant nonmajor bleeding was observed with tinzaparin (49 of 449 patients for tinzaparin vs 69 of 451 patients for warfarin; HR, 0.58 [95% CI, 0.40-0.84]; P = .004). CONCLUSIONS AND RELEVANCE Among patients with active cancer and acute symptomatic VTE, the use of full-dose tinzaparin (175 IU/kg) daily compared with warfarin for 6 months did not significantly reduce the composite measure of recurrent VTE and was not associated with reductions in overall mortality or major bleeding, but was associated with a lower rate of clinically relevant nonmajor bleeding. Further studies are needed to assess whether the efficacy outcomes would be different in patients at higher risk of recurrent VTE